Semaglyn vs Obeda in India — molecule, dose, price

Semaglyn vs Obeda: a structural comparison

If your doctor mentioned both Semaglyn and Obeda, or you've seen both listed on Tata 1mg, Apollo, or Pharmeasy, you're likely wondering how they differ. This page is a structural comparison — what's the same, what's different — and not a prescription or a recommendation for one over the other.

The headline fact: both Semaglyn and Obeda are Indian brands of the same active molecule, semaglutide. Semaglyn is marketed by Zydus Lifesciences, and Obeda is marketed by Dr Reddy's Laboratories. Both are CDSCO-approved for the Indian market and both follow the same weekly dosing schedule used globally for semaglutide.

Because the molecule is identical, the medical comparison is narrow — efficacy and side-effect profile track the molecule, not the brand. The practical comparison is about manufacturer, pharmacy availability across India, and price. For live pricing, see /price; for titration patterns, see /tools/titration; for eligibility framing, see /check. Final brand selection is a conversation with your prescriber.

What's the same

Structurally, Semaglyn and Obeda overlap on almost every clinical dimension because they share the same active molecule, semaglutide.

• Molecule and mechanism: Both are semaglutide, a GLP-1 receptor agonist. The label describes the same mechanism — slowing gastric emptying, modulating appetite signaling, and supporting glycaemic control.
• Dosing cadence: Both follow a once-weekly subcutaneous schedule, with a standard step-up titration (typically 0.25 → 0.5 → 1 → 1.7 → 2.4 mg over months). See /tools/titration for the general pattern.
• Side-effect profile: Commonly reported effects — nausea, reflux, constipation, fatigue during dose increases — track the molecule, not the brand. The Indian semaglutide side-effects guide applies to both.
• Regulatory pathway: Both are CDSCO-approved for the Indian market and dispensed via prescription through Apollo, Tata 1mg, Pharmeasy, Netmeds, and physical pharmacists.
• Storage and handling: Standard semaglutide cold-chain expectations apply per the label for both brands.

In short, if your doctor switches you between the two at the same dose, the medicine is the same; the box is different.

What's different

The meaningful differences are commercial and logistical, not pharmacological.

• Manufacturer: Semaglyn is from Zydus Lifesciences, a long-established Ahmedabad-based pharma company. Obeda is from Dr Reddy's Laboratories, headquartered in Hyderabad. Both are large Indian manufacturers with established quality systems, but they are distinct supply chains, distinct pens/devices (as per their respective labels), and distinct patient-support touchpoints.

• Pharmacy availability across India: Availability can vary week-to-week and city-to-city. In metros like Mumbai, Bengaluru, Delhi-NCR, Hyderabad and Chennai, both brands are typically listed on Apollo, Tata 1mg, Pharmeasy and Netmeds, though stock at any given dose strength fluctuates. In tier-2 cities, one brand may be easier to source than the other depending on the local distributor. Your neighbourhood pharmacist is often the fastest source of truth.

• Pricing in ₹: Indian semaglutide brand pricing shifts as new entrants launch and as manufacturers respond to competition from Wegovy India (Novo Nordisk) and others. Semaglyn and Obeda are not always priced identically across aggregators. For current ₹ figures across pen strengths, see /price, which we refresh against listed aggregator pricing.

• Patient-support packaging: Leaflets, dose-counter design, and any included guidance differ by label. Look at the carton your pharmacist hands you — counterfeit red flags to look for are covered separately on the /brands/semaglyn and /brands/obeda pages.

Questions worth asking your prescriber

If your doctor has mentioned either brand, these are useful conversation prompts — not a script to follow on your own:

• "Between Semaglyn and Obeda, is there a reason you're leaning toward one for my case?"
• "If my regular pharmacist is out of stock of one, is it reasonable to switch to the other at the same dose?"
• "Are there any differences in the pen device or injection technique I should learn?"
• "What side effects are common at the dose you're starting me on, and when should I call you?"
• "How will we decide when to step up the dose?"

Bring your current prescription, any prior GLP-1 history, and a list of other medications. For background reading before the appointment, the /check eligibility framing and /guides/semaglutide-side-effects guide are both useful. Final brand selection is a clinical decision — please consult your doctor.